Individuals who were given Trasylol to prevent excessive blood loss during coronary artery graft bypass surgery and suffered serious side effects may be able to recover compensation.
Trasylol side effects include serious kidney failure, congestive heart failure, stroke, death, pulmonary embolism, and renal failure.
Trasylol is a drug that is injected to prevent excessive blood loss during heart bypass surgery. Its works by slowing down fibrinolysis, the process that leads to the breakdown of blood clots. Use of this drug is intended to decrease the need for blood transfusions during surgery.
A Trasylol warning was issued in December 2006 and it was permanently recalled in May 2008.
Manufactured by Bayer, Trasylol is an injection used in to prevent excessive blood loss during heart bypass surgery. However, Trasylol has put patients at an increased risk of death. Studies have shown that more than 6% of patients injected with the drug died within 30 days of surgery.
In Nov. 2007, the drug was removed from the market after a Canadian study reported that patients injected with Trasylol were dying more often than other patients in the study. Prior to the Canadian study, Dr. Dennis Mangano provided the FDA with research that Trasylol increased the chance of kidney failure. His study also reported that the drug increased by chance of death by 50%. Bayer representatives met with Mangano, defended Trasylol and allowed it to stay on the market. However, Bayer failed to alert the FDA of their own studies that confirmed the doctor’s findings. Research conducted by Bayer found that risk of death in patients injected with Trasylol was 64% higher than other patients.
After Mangano’s meeting with Bayer, the FDA issued Trasylol a black box warning to alert patients of the increased risk of death and kidney failure. The label also advised that Trasylol should only be used for those at a high risk of blood loss during surgery.